About that whole Shortage thing The interesting dynamic at play here isHims doesnt share investor concerns around the massive business risk associated with compounding GLP-1s during a shortage and capitalizing on a technicality
That may sound like a dramatic prediction, but it is the conclusion I reached after reviewing a document we recently uncovered (January 12th, 2026) regulatory filing submitted by Novo Nordisk to the U.S
In fact, LC protects against ROS-related harm to DNA and cell membranes
This update provides a detailed pathway for tackling the various dilemmas around GLP-1 RAs that we are faced with in clinical practice
Whats missing is strong, long-term evidence that long-term microdosing produces comparable outcomes in weight, blood glucose control, and reduction of cardiovascular risk
L-Carnitine enhances mitochondrial function by promoting increased fat burning